Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study

Goldman, J.W., Garassino, M.C., Chen, Y. et al. (17 more authors) (2020) Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. Lung Cancer, 149. pp. 46-52. ISSN 0169-5002

Abstract

Metadata

Authors/Creators:
  • Goldman, J.W.
  • Garassino, M.C.
  • Chen, Y.
  • Özgüroğlu, M.
  • Dvorkin, M.
  • Trukhin, D.
  • Statsenko, G.
  • Hotta, K.
  • Ji, J.H.
  • Hochmair, M.J.
  • Voitko, O.
  • Havel, L.
  • Poltoratskiy, A.
  • Losonczy, G.
  • Reinmuth, N.
  • Patel, N.
  • Laud, P.J. ORCID logo https://orcid.org/0000-0002-3766-7090
  • Shire, N.
  • Jiang, H.
  • Paz-Ares, L.
Copyright, Publisher and Additional Information: © 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Small-cell lung cancer; Durvalumab; Platinum-etoposide; CASPIAN; Patient-reported outcomes; Health-related quality of life
Dates:
  • Accepted: 6 September 2020
  • Published (online): 10 October 2020
  • Published: 10 September 2020
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Science (Sheffield) > School of Mathematics and Statistics (Sheffield)
Depositing User: Symplectic Sheffield
Date Deposited: 19 Oct 2020 15:27
Last Modified: 19 Oct 2020 15:27
Status: Published
Publisher: Elsevier BV
Refereed: Yes
Identification Number: https://doi.org/10.1016/j.lungcan.2020.09.003
Related URLs:

Download

Share / Export

Statistics